Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
Brief Summary: Left ventricular hypertrophy (LVH) is common in people with type 2 diabetes (70%) and is the strongest independent risk factor for cardiovascular events and all-cause mortality that there is. It is worse than triple vessel coronary disease. LVH often occurs in patients with "normal" blood pressures (BP). Apart from BP, the other three main factors causing LVH are insulin resistance, obesity and cardiac preload. Dapagliflozin reduces ALL four factors known to promote LVH i.e. Dapagliflozin reduces weight, glycaemia, preload and blood pressure and is therefore the ideal agent to reduce LVH since it uniquely attacks all four known mediators of LVH. This trial will investigate the ability of dapagliflozin to regress LVH in 64 participants with normotensive diabetes. This will be done by seeing if dapagliflozin reduces left ventricular mass as measured by cardiac magnetic resonance imaging (MRI). This trial may identify a novel way to reduce the strong independent risk factor of LVH which often persists despite optimum medical therapy in patients with diabetes. If dapagliflozin does reduce LVH, this would be a key sign of which subgroup of patients with diabetes (those with LVH) should be especially targeted with dapagliflozin.

64 participants with type 2 diabetes and LVH will be recruited through the Scottish Diabetes Research Network (SDRN), Scottish Primary Care Research Network (SPCRN) and other routes, in this single centre study. Participants will be randomised to receive either 10mg dapagliflozin or placebo daily for 12 months. Cardiac MRI will be performed at baseline and at 12 months, this will be assessed for the primary outcome of change in left ventricular mass. Secondary outcomes will examine change in 24 hour blood pressure and weight.


Options:
A: Arm Label: Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
D: Arm Label: Omarigliptin; Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B